Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Clinical trial NCT05130866 · TERMINATED
Trial details
- NCT number
- NCT05130866
- Sponsor
- Recursion Pharmaceuticals Inc.
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-20
- Primary completion
- 2025-08-18
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.